SPOTLIGHT: FDA warns J&J unit on heart drug marketing


Promotional pens and mouse pads landed a Johnson & Johnson unit it hot water with the FDA. The tchotchkes, which featured the heart drug Natrecor, didn't include warnings about its "numerous risks," the agency said. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.